Vivos Therapeutics
VVOS
About: Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Employees: 109
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
58% more capital invested
Capital invested by funds: $802K [Q1] → $1.27M (+$466K) [Q2]
2.03% more ownership
Funds ownership: 4.78% [Q1] → 6.81% (+2.03%) [Q2]
10% less funds holding
Funds holding: 20 [Q1] → 18 (-2) [Q2]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Ascendiant Capital
Lucas Ward
|
$6.5
|
Buy
Maintained
|
9 Sep 2025 |
Financial journalist opinion
Based on 3 articles about VVOS published over the past 30 days
